Glutamate racemase (MurI) catalyzes the interconversion of L-glutamate to D-glutamate, one of the essential amino acids present in the peptidoglycan. In addition to this essential enzymatic function, MurI from Escherichia coli, Bacillus subtilis and Mycobacterium tuberculosis inhibit DNA gyrase activity. A single gene for murI found in the Mycobacterium smegmatis genome was cloned and overexpressed in a homologous expression system to obtain a highly soluble enzyme. In addition to the racemization activity, M. smegmatis MurI inhibits DNA gyrase activity by preventing DNA binding of gyrase. The sequestration of the gyrase by MurI results in inhibition of all reactions catalyzed by DNA gyrase. More importantly, MurI overexpression in vivo in mycobacterial cells provides protection against the action of ciprofloxacin. The DNA gyrase-inhibitory property thus appears to be a typical characteristic of MurI and would have probably evolved to either modulate the function of the essential housekeeping enzyme or to provide protection to gyrase against gyrase inhibitors, which cause double-strand breaks in the genome.
Introduction
All bacteria obtain their structural integrity from the peptidoglycan layer, a large polymeric structure that is located between the cytoplasmic and the outer membranes of the cell wall. Peptidoglycan is formed from linear chains of two alternating amino sugars, namely N-acetylglucosamine and N-acetylmuramic acid, to which a small group of amino acids (stem peptide) consisting of L-alanine, D-alanine, D-glutamate and either lysine or diaminopimelic acid are covalently attached (Meroueh et al., 2006) . Glutamate racemase (MurI) catalyzes the interconversion of L-glutamate to D-glutamate, one of the integral components present in peptidoglycan. It is ubiquitously inherited in bacteria although with undetectable activity, except in some lactobacilli (Gallo & Knowles, 1993) .
By virtue of being unique to bacteria, peptidoglycan and the enzymes involved in its biosynthesis have been considered to be attractive targets for the design and development of new antibacterial agents. Approaches in this direction include rational, structure-based drug design to inhibit the synthesis of the stem peptide portion of the peptidoglycan precursor (Tanner et al., 1996; Zeng et al., 1998; Reck et al., 2001) . MurI, a provider for D-glutamate, has been shown to be important in bacteria including pathogenic species (Hoskins et al., 1999; Glavas & Tanner, 2001) . Being an essential enzyme, it is already used as a target for antibacterial drug discovery. The first discovered, moderately potent MurI inhibitors competitively interfered with the L/D transformation (Tanner & Miao, 1994; Glavas & Tanner, 1997; de Dios et al., 2002) . The design of D-glutamate-based analogues and their structure activity relationship studies led to the discovery of several potential MurI inhibitors (Glavas & Tanner, 1997; de Dios et al., 2002) .
Besides the racemization function, few glutamate racemases have been shown to possess an additional property of gyrase inhibition. Escherichia coli MurI was the first one to be shown to inhibit E. coli gyrase, but only in the presence of the peptidoglycan precursor (Ashiuchi et al., 2002) . Subsequently, one of the two glutamate racemases from Bacillus subtilis, the YrpC isozyme, was shown to influence the activity of DNA gyrase in a precursor independent fashion (Ashiuchi et al., 2003) . MurI from Mycobacterium tuberculosis inhibits DNA gyrase by preventing the DNA-binding activity of the enzyme (Sengupta et al., 2006) . Gyrase inhibition seems to be an additional attribute of some of the glutamate racemases, but not all, as Glr isozyme from B. subtilis has no effect on gyrase activity (Ashiuchi et al., 2003) .
MurI from M. tuberculosis cloned in E. coli was found to be in the insoluble inclusion bodies (Sengupta et al., 2006) . Attempts to express the protein in soluble form in E. coli were unsuccessful. The active enzyme was recovered after urea refolding and was then used for biochemical characterization. It is important to obtain the protein in soluble form and in large quantities to carry out structural studies and detailed characterization.
Like M. tuberculosis, the Mycobacterium smegmatis genome contains a single gene for glutamate racemase although the genome of the latter is larger. Understanding the characteristics of M. smegmatis MurI is important because M. smegmatis is often used as a surrogate for M. tuberculosis for a variety of studies. Comparison of the properties of MurI from both the species would form the basis for its use for in vivo screening of antimycobacterial compounds.
In the present study, M. smegmatis MurI has been expressed and purified in soluble form with high specific activity. The studies reveal that MurI from M. smegmatis is also a bifunctional enzyme. It inhibits DNA gyrase in addition to its racemization activity. Further, overexpression of the enzyme in M. smegmatis provides protection to the organism against fluoroquinolones.
Materials and methods

Bacterial strains and plasmids
Escherichia coli strains DH5a and M. smegmatis mc 2 155 strains were used for cloning and overexpression of M. smegmatis MurI, respectively. Genomic DNA from M. smegmatis mc 2 155 was isolated as described (Madhusudan et al., 1994) . The murI gene was cloned in the pJAM2 vector (Triccas et al., 1998) . pBR322 and pUC18 plasmids were used for the biochemical assays.
Enzyme and substrate preparation
Escherichia coli DNA gyrase subunits, GyrA and GyrB, were purified as described (Maxwell & Howells, 1999) . Mycobacterium smegmatis DNA gyrase was purified by the method standardized before (Manjunatha et al., 2002) . Supercoiled pUC18 and pBR322 were prepared by standard protocols (Sambrook et al., 1989) . The amplicon was subjected to NdeI digestion, followed by end filling with Klenow polymerase, and ligated to an ScaI digested pJAM2 vector to generate a pJAM2-msmurI construct.
Cloning of murI
Expression and purification of MurI
The M. smegmatis mc 2 155 cells harboring the pJAM2-msmurI construct were grown in Middle brook 7H9 media. The cells were harvested, resuspended in sonication buffer containing 50 mM Tris-HCl pH-8.0, 1 mM potassium glutamate, 0.1 mM phenyl methane sulfonyl fluoride, 0.5 mM MgCl 2 , and sonicated. Lysis was followed by ultracentrifugation at 100 000 g at 4 1C for 3 h. The supernatant was subjected to 60% ammonium sulfate fractionation. The pellet containing MurI was dialyzed against buffer A (50 mM Tris-HCl pH-8.0, 0.2% 2-mercaptoethanol, 0.1 mM phenyl methane sulfonyl fluoride, 10% glycerol) and loaded onto a MonoQ column, washed with buffer A containing 200 mM NaCl and the enzyme was eluted with a gradient of 200-500 mM NaCl. The peak fractions containing MurI were pooled and dialyzed against the same buffer, reloaded onto MonoQ column and eluted with a shallow gradient of 250-350 mM NaCl. The fractions containing MurI were pooled and subjected to 0-60% ammonium sulfate fractionation. The pellet was dissolved in 2 mL of the buffer A, dialyzed and loaded onto a Sephacryl S100 gel filtration column. The eluted fractions containing MurI were pooled, dialyzed, concentrated and stored at À 70 1C.
Racemization activity
The racemization activity was assessed by a coupled assay as described previously (Sengupta et al., 2006) . MurI was incubated in the presence of D-glutamate for 30 min at 37 1C and then rapidly heated to inactivate the enzyme and further assayed for L-glutamate using NAD 1 /L-glutamate dehydrogenase. The increase in A 340 nm was monitored for 10 min at 25 1C using a Beckman DU640 UV/vis spectrophotometer.
DNA supercoiling and relaxation reactions
Supercoiling assays were carried out at 37 1C with 300 ng of relaxed pUC18 and 10 nM DNA gyrase from either M. smegmatis in supercoiling buffer [Buffer S: 35 mM TrisHCl pH 7.5, 5 mM MgCl 2 , 25 mM potassium glutamate, 2 mM spermidine, 2 mM ATP, 50 mg L À1 BSA and 90 mg L
À1
yeast tRNA in 5% (v/v) glycerol]. Relaxation assays were carried out with 150 nM of gyrase using supercoiled pBR322 in buffer S devoid of ATP, either in the presence or in the absence of MurI for 60 min at 37 1C and terminated with 0.6% sodium dodecylsulfate (SDS). The assay mixtures were resolved on 1% agarose gel in 40 mM Tris-actetate buffer containing 1 mM EDTA.
Electrophoretic mobility shift assay (EMSA)
Assays were carried out using an end-labeled 240-bp DNA fragment encompassing the strong gyrase site (SGS) from pBR322. One nanomolar of labeled DNA was incubated with 100 nM of DNA gyrase either in the absence or in the presence of different concentrations of MurI in buffer S for 30 min at 4 1C, followed by electrophoresis on 4% native polyacrylamide gel as described (Sengupta et al., 2006) . The free DNA and bound complexes were quantitated using a phosphorimager.
Cleavage reactions
DNA cleavage assays were carried out in buffer S with a supercoiled pBR322 substrate or radiolabeled 240-bp SGS for 30 min at 30 1C, and the gyrase-DNA complex was trapped by adding 0.2% SDS, followed by proteinase K (90 mg mL À1 ) digestion for 30 min. In case of drug-induced cleavage reactions, ciprofloxacin (30 mg mL À1 ) was included in the assay. The reaction mixtures were resolved on 1% agarose gel or 8% urea-polyacrylamide gel electrophoresis (PAGE). The substrate and cleaved DNA products were quantitated using a phosphorimager.
ATPase assay
The DNA-stimulated ATPase activity of DNA gyrase was monitored in buffer S containing 2 mM ATP, 10 mg mL À1 DNA (240 bp from pBR322) and 0.02 mCi of [g-32 P] ATP (3000 Ci mmol À1 ). In order to assess the intrinsic ATPase activity, 1 mM GyrB was used while DNA and GyrA were omitted. The assays were carried out as described earlier (Sengupta et al., 2006) . The aqueous layer (1.0 mL) was resolved on polyethyleneimine-cellulose by thin-layer chromatography using 1.2 M LiCl, and 0.1 mM EDTA as the chase buffer. The spots corresponding to ATP and P i were quantitated using a phosphorimager.
Growth profiles and cytotoxicity assays
Mycobacterium smegmatis mc 2 155 cells containing either the pJAM2 vector or the pJAM2-msmurI construct were grown in Middlebrook 7H9 media supplemented with 0.4% glucose at 37 1C, and growth was monitored by measuring A 600 nm after every 3 h. The effect of MurI on the toxicity caused by drugs (ciprofloxacin and mitomycin C) was tested by spotting various concentrations of the drug on a lawn of M. smegmatis mc 2 155 containing either the pJAM2 vector or pJAM2-msmurI constructs. The cultures were grown to the mid-logarithmic phase and then 1% inoculums were poured onto Middlebrook 7H9-soft agar plates (0.8% agar) containing appropriate antibiotics. The plates were preincubated for drying before the spotting. Equal volumes (2 mL) of drugs from the stock solutions of varying concentrations were spotted on the lawn of cells, and the diameters of the zones of inhibition were measured and tabulated to compare the potency of the drugs for the M. smegmatis transformants.
Results
Purification of M. smegmatis MurI
The recombinant glutamate racemase was overexpressed from the pJAM2-msmurI construct in the M. smegmatis mc 2 155 strain. Constitutive high-level expression was obtained without requiring acetamide-mediated induction (Fig. 1) . The identity of the protein was confirmed by the standard tryptic mass fingerprinting technique (not shown). The recombinant protein was found totally in the soluble fraction in contrast to the M. tuberculosis enzyme expressed in E. coli. It was purified to apparent homogeneity and racemase activity was assayed by the glutamate dehydrogenase coupled assay. The specific activity was determined to be 3 U mg À1 of the enzyme, 1 U being defined as the amount of enzyme required to convert 1 mmol of substrate into product min À1 . The soluble protein was found to be 10-fold more active when compared with urea-refolded M. tuberculosis MurI.
Mycobacterium smegmatis MurI inhibits DNA gyrase activity
Alignment of the M. smegmatis MurI sequence with that of the M. tuberculosis enzyme revealed that they share 82% identity at the amino acids level. To test the effect of M. smegmatis MurI on supercoiling activity, mycobacterial DNA gyrase was preincubated with MurI before the addition of relaxed pUC18. MurI inhibited supercoiling activity of DNA gyrase in a dose-dependent fashion (Fig. 2a) . To test the effect of MurI on DNA gyrase-mediated relaxation, DNA gyrase was preincubated with MurI prior to the addition of a supercoiled pBR322 DNA substrate. MurI was found to inhibit the DNA relaxation activity of gyrase as well (Fig. 2b) . MurI inhibited the decatenation activity and also the activity of gyrase from a heterologous source i.e. from E. coli at comparable levels (not shown). Hence, MurI inhibits DNA gyrase across the species barrier unlike the toxins CcdB and microcin B17 , which are specific inhibitors of E. coli DNA gyrase.
MurI inhibits at the step of DNA binding
To assess the effect of MurI on gyrase-DNA complex formation, EMSAs were performed by preincubating DNA gyrase with different concentrations of MurI, prior to the addition of DNA. MurI inhibited the formation of the gyrase-DNA noncovalent complex in a dose-dependent manner (Fig. 3a) . If DNA binding by gyrase is the target of MurI action, the DNA-stimulated ATPase activity of the enzyme should be affected while its intrinsic activity should be unaltered. Reactions were carried out in the presence of a linear DNA substrate as described in 'Materials and methods' . MurI inhibited the DNA-stimulated ATPase activity of DNA gyrase (Fig. 3b) . However, as expected, the intrinsic ATPase activity of DNA gyrase was not altered in the presence of MurI (Fig. 3c) .
To test the effect of MurI at the cleavage step, DNA gyrase was preincubated with MurI and the cleavage assays were performed both with the supercoiled plasmid DNA and the radiolabeled linear DNA substrates. Ciprofloxacin is known to arrest DNA gyrase at the cleavage step and calcium (Ca 21 ) ions inhibit the religation and stimulate the DNA cleavage activity of the enzyme (Gmunder et al., 1995; Lewis et al., 1996; Maxwell, 1999) . SDS and proteinase K treatment removes the covalently attached protein and a cleaved DNA fragment can be visualized on the gel. Unlike ciprofloxacin and calcium ions, MurI did not stimulate DNA gyrasemediated cleavage (Fig. 3d, compare lanes 3 with lanes 4 and  5) . MurI also abrogated ciprofloxacin-induced cleavage on a linear DNA substrate (Fig. 3e) . From all these observations, it is concluded that M. smegmatis MurI also inhibits the DNA-binding activity of DNA gyrase in a manner similar to that of M. tuberculosis MurI. Because, DNA binding is the first step in the catalytic cycle of gyrase, all the subsequent steps are affected in the presence of MurI. Moreover, ciprofloxacin targets the gyrase-DNA covalent complex for stabilization, and MurI interaction with DNA gyrase prevents ciprofloxacin action in vitro.
MurI protects the bacteria from the action of ciprofloxacin
Because MurI appears to protect against ciprofloxacin action in vitro (Fig. 3d and e) , to evaluate the scenario in vivo, the cytotoxic action of quinolones was tested by (Table 1 ). The reduced diameters of zone of inhibition with ciprofloxacin in case of MurI overexpressing cells indicate that MurI overexpression leads to increased resistance against ciprofloxacin. MurI-mediated protection was specific towards DNA damage caused by trapped gyrase-DNA covalent complexes as MurI did not provide protection against mitomycin C, a general DNAdamaging agent (Table 1) . These in vivo experiments support the in vitro data that MurI prevents the DNA-binding activity of gyrase and by doing so, protects gyrase against the cytotoxic action of gyrase poison, ciprofloxacin. The growth profile of M. smegmatis overexpressing MurI was compared with the cells harboring only the pJAM2 vector. There were no significant differences in growth upon MurI expression and plasmid topology remained unaltered (not shown).
From these results, it appears that MurI-mediated inhibition of DNA gyrase could be transient and gyrase is able to overcome it probably by means of relaxation-stimulated transcription (RST) (Unniraman & Nagaraja, 1999) .
Discussion
Mycobacterium smegmatis glutamate racemase exhibits a dual role by possessing racemase activity and DNA gyrase inhibition. Thus, in this respect it is similar to the glutamate racemases from E. coli, M. tuberculosis and YrpC from B. subtilis (Ashiuchi et al., 2002 (Ashiuchi et al., , 2003 Sengupta et al., 2006) . However, unlike the E. coli enzyme, the M. smegmatis MurI enzyme appears to be active independent of any peptidoglycan precursor as far as racemization as well as gyrase inhibitory properties are concerned. The first report on inhibition of DNA gyrase by glutamate racemase (Ashiuchi et al., 2002) was rather surprising as the enzyme appeared to have no role in DNA transaction processes and seemed to be dedicated only to cell wall component biosynthesis. Subsequent studies from the same group with the enzyme from B. subtilis (Ashiuchi et al., 2003) , the authors' studies with M. tuberculosis MurI (Sengupta et al., 2006) and the present work with the M. smegmatis enzyme indicate that inhibition of DNA gyrase activity is a typical characteristic of at least one group of glutamate racemases. The interaction and inhibitory effect of MurI seems to be specific to gyrase and conserved across the species barrier. Because, MurI from distantly related organisms exhibit this bifunctional behavior, the bifunctionality does not seem to be a mere coincidence and may have some functional significance. It is suggested that the gyrase-inhibitory properties of glutamate racemases might have evolved in eubacteria to serve some important physiological purpose. DNA gyrase is a vital and indispensable enzyme in bacteria functioning in several DNA transaction processes. Among a large repertoire of the gyrase inhibitors, coumarins and quinolones have been studied extensively with respect to their mechanism of action (Lewis et al., 1996; Maxwell, 1999) . Now, a newer group of inhibitors is emerging with the discovery of the chromosomally encoded inhibitors such as GyrI (Nakanishi et al., 1998; ), MfpA (Montero et al., 2001; Hegde et al., 2005) , Qnr (Martinez-Martinez et al., 2003; Tran et al., 2005; Arsene & Leclercq, 2007) and MurI (Ashiuchi et al., 2002 (Ashiuchi et al., , 2003 Sengupta et al., 2006) . In spite of having no sequence or structural similarities, all these endogenous inhibitors share a common feature, as their mode of inhibition is to prevent binding of gyrase to DNA. Thus, none of these proteins are cytotoxic, as they do not arrest the enzymatic step of DNA gyrase. Cytotoxicity usually arises due to induction and accumulation of double-strand breaks in the genome following the trapping of gyrase in the form of enzyme-DNA covalent complexes, which form roadblocks to the cellular DNA transaction machineries.
In the present study, soluble mycobacterial MurI is purified by overexpressing it in M. smegmatis itself. Although it inhibits DNA gyrase activity in vitro, MurI protects M. smegmatis against the action of ciprofloxacin in vivo. These studies indicate that MurI may be a survival strategy used by the cell to safeguard the essential housekeeping enzyme, DNA gyrase from the gyrase-targeting poisons. Alternatively, MurI could bind transiently to DNA gyrase to sequester it away from DNA in situations wherein excessive supercoiling has to be modulated. Another plausible explanation is that MurI-mediated sequestration of gyrase serves as a 'check point' during the process of cell Table 1 . Diameters of zone of inhibition for different dilutions of ciprofloxacin and mitomycin C on a lawn of Mycobacterium smegmatis strain harboring either the vector pJAM2 or pJAM2-msmurI pJAM2 vector (mm) pJAM2-msmurI (mm) Ciprofloxacin (mg) 0.5 15 AE 0.6 10 AE 0.5 0.4 13 AE 0.5 9 AE 0.6 0.3 10 AE 0.6 5 AE 0.5 0.1 8 AE 0.5 3 AE 0.6 Mitomycin C (mg) 20 12 AE 0.8 12 AE 0.5 10 9 AE 0.7 9 AE 0.4 5 7 AE 0.6 8 AE 0.1 2.5 5 AE 0.7 5 AE 0.6 1.25 4 AE 0.5 4 AE 0.2
Mycobacterium smegmatis cultures were grown in Middlebrook 7H9 broth till mid-logarithmic phase at 37 1C and then poured onto soft agar plates to form the lawn. Different dilutions of the drugs were spotted and then the plates were incubated for 3-4 days to get defined zones of inhibition.
division. In this model, the cell division and DNA replication would be coordinated by modulation of gyrase. An alarming increase in the emergence of multi-drug-resistant strains of M. tuberculosis and continuing high worldwide incidence of tuberculosis has motivated an increasingly active search for novel drug targets. Inhibition of the bacterial cell wall peptidoglycan biosynthesis pathway seems to be one of the attractive targets. MurI is already being considered as a target for designing new antibacterial drugs as it provides D-glutamate, a key building block for peptidoglycan in bacteria. Because MurI protects gyrase from the cytotoxic effect of quinolone drugs, blocking MurI activity along with antigyrase agents might be a more effective cellkilling strategy, providing a synergistic effect. The production and purification of mycobacterial MurI in large amounts in soluble form is a step forward to the design of high-throughput screening assays for testing potential MurI inhibitors with the aim of developing new antimycobacterial compounds.
